Oxford tech firm gets £1.5m Series A boost with London's Downing Ventures
Oxford’s The Electrospinning Company has received £1.5m funding led by London-based venture capital firm Downing Ventures.
The funding has been made available alongside VC firm MidVen, Newable Private Investing and the STFC.
The company uses ‘electrospinning’ tech to design, develop and manufacture biomaterials, known as ‘nanofibre scaffolds’. These are made from synthetic polymers that are implanted into the human body; aiming to help medical patients and procedures.
Ann Kramer, chief executive officer of the Electrospinning Company, said: “We are excited about the prospects this new investment will bring for what we believe are highly flexible and extremely beneficial medical products.
“We are at an important growth inflection point for our business, as we enhance our technology platform and capacity.”
Ann added: “The funding will help us maintain the highest possible standards as we grow sales of existing product, increase our customer offer and develop new biomaterials.
“The insight of Will Brooks and the team at Downing Ventures - in terms of their knowledge of the healthcare sector and their experience funding companies within it - gives us great confidence and we look forward to working with them.”
The ‘scaffolds’ are designed to mimic the body’s natural extracellular matrix, which exists to provide support and signalling to surrounding cells, and the biomaterials are tailored so that they degrade or reabsorb naturally once the patient has healed.
Tendon surgery is just one example where the company’s scaffold technology is being used in combination with traditional orthopaedic medical devices to improve the success rate of the medical procedure.
Following earlier work with the University of Sheffield and the LVPrasad eye clinic in India, the company has also initiated a new project to develop a synthetic membrane that resembles amniotic membrane.
Will Brooks, investment director at Downing Ventures, concluded: “The Electrospinning Company is a brilliant example of the type of innovative technology and team that has the potential to deliver the return on investment we are looking for on behalf of our investors.
“Their established track record in the US really stood out to us and we plan to use our own experience of the US market to help them expand further, as well as in other markets that they have not yet pushed into.”
Want your business, product or service to be seen regionally and nationally? Bdaily helps you get your story in front of the right audience, every day. Find out how Bdaily can help →
Join more than 55,000 subscribers by signing up to our daily bulletin each morning here.
Enjoy the read? Get Bdaily delivered.
Sign up to receive our popular morning London email for free.
Taking advantage of the opportunities ahead
Accountability isn’t the enemy of empathy
Act now to avoid a last-minute tax scramble
How inner-city living can transform a city by the sea
Artificial intelligence's value is the time it gives back
Why we must break the magnetic pull of London
AI scepticism is healthy - inaction isn't
What does NPPF mean for planning gain and pricing?
What new NPPF rules mean for landowners
The hidden cost squeezing Britain's economy
Teesside deserves more than cashback devolution
Construction must be built on commercial discipline